Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved.
Why Monopoly Game Owner Hasbro’s Shares Are Diving Today
Hasbro reports Q4 FY23 results with sales down 23%, operating loss of $1.2B, while raising gross savings target for 2025.
Toyota Shakes Up Subsidiary Leadership: Daihatsu’s Top Executives Exit Amid Scandal
Toyota's subsidiary Daihatsu's President and Chairman will step down. Commercial Japan Partnership Technologies Corporation (CJPT) has accepted a request initiated by Daihatsu Motor for removal from CJPT in light of procedural irregularities in certification applications.
Why Electronic Systems Designer Cadence Shares Are Down Premarket Today
Cadence Design Systems reported $1.069B revenue, 43% operating margin, & $1.38 EPS. Outlook: $990M-$1.01B revenue, $1.10-$1.14 EPS for Q1 FY24.
Market Correction Due: Stocks Are Running Out Of Reasons To Move Higher, Analyst Says
Stocks running out of reasons to move higher, market correction imminent. Internal indicators signal sell, could take S&P 500 back to 4,600.
Disney Epic: Activist Shareholders Prepare For Boardroom Blitz
Hedge funds take their boardroom fight to Disney shareholders in April 3 vote.
Eli Lilly’s Weight Loss Drug Tripeptide Is Expanding Market Share, Analyst Outline What Lies Ahead
Track Eli Lilly's tripeptide success. Weekly updates on Mounjaro and Zepbound prescriptions in the GLP-1 category. Analyst predicts $12.78 billion in fiscal year 2024 tripeptide revenues.
This Analyst Slightly Lowers AstraZeneca Forecast Amid Earnings Concerns, Although Still Bullish on Future Growth Potential
AstraZeneca reported Q4 2023 sales of $12.02B, up 7%, below consensus. Excluding COVID-19 drugs, revenue increased by 16%. Core EPS was $1.45, missing consensus. BMO Capital maintains Outperform rating.
Wall Street Extends Record Highs Ahead Of Key Inflation Report, Bitcoin Hits $50,000, NVIDIA Surpasses Amazon: What’s Driving Markets Monday?
Wall Street kicked off the week on a high note, with the S&P 500 and Nasdaq 100 reaching new highs in anticipation of the January inflation report scheduled for this Tuesday.
Willis Towers Watson To See Short-Term Success Amid Defined Benefit Plan Shifts – Analyst Upgrades Stock
Analyst Zaremski upgraded Willis Towers Watson to Market Perform, predicting continued growth and strong performance in broking and DB segments.